| Drug Name |
Sunitinib |
| Drug ID |
BADD_D02100 |
| Description |
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. |
| Indications and Usage |
For the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EX01 |
| DrugBank ID |
DB01268
|
| KEGG ID |
D08552
|
| MeSH ID |
D000077210
|
| PubChem ID |
5329102
|
| TTD Drug ID |
D0R0MW
|
| NDC Product Code |
Not Available |
| UNII |
V99T50803M
|
| Synonyms |
Sunitinib | 5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide | Sunitinib Malate | Sutent | SU 11248 | SU011248 | SU 011248 | SU-011248 | SU11248 | SU-11248 |
